MBCC   |  March 13, 2020   Study Design for the Phase III GLORIA Trial of OBI-822/OBI-821 Vaccine Combination The goal of the study is to determine the effect of adagloxad simolenin administered with the potent adjuvant OBI-821 as a therapeutic vaccine treatment on improving invasive disease-free survival in the study population. Read more ADVERTISEMENT   Barbara Bigelow Discusses her Journey with Triple Negative Breast Cancer After a serious adverse reaction to a clinical trial put her in critical condition, Barbara Bigelow now shows no signs of breast cancer and is no longer on any cancer medications. Read more